Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma

CONCLUSIONS: The combination of dasatinib 60 mg/m2/dose daily and ganitumab 18 mg/kg every two weeks was safe and tolerable. This combination had a disease control rate of 22% at five months.PMID:37398992 | DOI:10.1158/1078-0432.CCR-23-0709

Source: Cancer Control - July 3, 2023 Category: Cancer & Oncology Authors: Srivandana Akshintala R Taylor Sundby Donna Bernstein John W Glod Rosandra N Kaplan Marielle E Yohe Andrea M Gross Joanne Derdak Haiyan Lei Alexander Pan Eva Dombi Isabel Palacio-Yance Kailey R Herrera Markku M Miettinen Helen X Chen Seth M Steinberg Lee Source Type: research